Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011.

@article{Washio2001IdentificationOH,
  title={Identification of human drug-metabolizing enzymes involved in the metabolism of SNI-2011.},
  author={Takuo Washio and Hirohiko Arisawa and Kazuhiro Kohsaka and Hirokazu Yasuda},
  journal={Biological \& pharmaceutical bulletin},
  year={2001},
  volume={24 11},
  pages={
          1263-6
        }
}
In vitro studies were conducted to identify human drug-metabolizing enzymes involved in the metabolism of SNI-2011 ((+/-)-cis-2-methylspiro [1,3-oxathiolane-5,3'-quinuclidine] monohydrochloride hemihydrate, cevimeline hydrochloride hydrate). When 14C-SNI-2011 was incubated with human liver microsomes, SNI-2011 trans-sulfoxide and cis-sulfoxide were detected as major metabolites. These oxidations required NADPH, and were markedly inhibited by SKF-525A, indicating that cytochrome P450 (CYP) was… Expand
Identification of human cytochrome P450 enzymes involved in the metabolism of IN-1130, a novel activin receptor-like kinase-5 (ALK5) inhibitor
TLDR
It is concluded that metabolism of IN-1130 is mediated by CYP3A4, CYP2C8, CyP2D6*1, and CYP 2C19, and the production of metabolites were significantly inhibited by specific CYP inhibitors. Expand
Drug metabolism by flavin-containing monooxygenases of human and mouse
TLDR
Identification of roles for FMO1 and FMO5 in endogenous metabolism has implications for drug therapy and initiates an exciting area of research. Expand
Pharmacokinetics, Metabolism, and Excretion of the Antiviral Drug Arbidol in Humans
TLDR
Possible drug interactions between arbidol and CYP3A4 inhibitors and inducers are indicated and microsomal incubation experiments demonstrated that the liver and intestines were the major organs that metabolize ar bidol in humans. Expand
Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.
TLDR
Flavin-containing monooxygenase oxygenates drugs and xenobiotics containing a "soft-nucleophile", usually nitrogen or sulfur, and cytochrome P450 is the major contributor to oxidative xenobiotic metabolism. Expand
Genetic variants of flavin-containing monooxygenases:consequences for drug metabolism
The metabolism of the anti-tubercular drug, thiacetazone (TAZ) by human FMOs in vitro and the disposition of TAZ in vivo in mice were studied. Reverse phase chromatography confirmed TAZ to be aExpand
SPECIES DIFFERENTIAL STEREOSELECTIVE OXIDATION OF A METHYLSULFIDE METABOLITE OF MK-0767 [(±)-5-[(2,4-DIOXOTHIAZOLIDIN-5-YL)METHYL]-2-METHOXY-N-[[(4-TRIFLUOROMETHYL)PHENYL]METHYL]BENZAMIDE], A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DUAL AGONIST
TLDR
Results indicated that M25 oxidation was more sensitive to heat inactivation at pH 8 and 8.7 in rat and dog liver microsomes than in human and monkey livermicrosomes, consistent with the species difference in involvement of FMOs. Expand
5.05 – Principles of Drug Metabolism 1: Redox Reactions
In this chapter the major enzymes that metabolize drugs or other xenobiotics by catalyzing either their oxidation or reduction are profiled in terms of basic structure, co-factors, substrateExpand
Characterization of Human Flavin-Containing Monooxygenase (FMO) 3 and FMO5 Expressed as Maltose-Binding Protein Fusions
TLDR
This report serves as the first direct comparison between Supersome FMOs and the corresponding MBP fusions and the first report of a detergent-based activation of kcat/Km that corresponds to changes in oligomerization. Expand
Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug
The authors investigated the pharmacokinetics and metabolism of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide (IN-1130), a novel ALK5 inhibitor, which suppressesExpand
Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order
TLDR
An in silico system for the prediction of CYP2E1-mediated reaction using a two-dimensional template derived from substrate structures to predict the relative abundance as well as the regioselectivity of human CYP 2E1 reactions with high fidelities is constructed. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 24 REFERENCES
Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
TLDR
Nine chemical inhibitors were selected based on literature data and were examined for their specificity toward cytochrome P450-mediated reactions in human liver microsomes and troleandomycin proved to be the most specific for testosterone 6 beta-hydroxylation. Expand
Extrahepatic Metabolism of Drugs in Humans
TLDR
The metabolic profile and sites of enzymatic reactions for each drug should be determined and extrahepatic metabolism has been demonstrated for numerous drugs. Expand
Differential inhibition of individual human liver cytochromes P-450 by cimetidine.
TLDR
In vitro studies showing a high variability in the effect of cimetidine on drug metabolism by individual human liver cytochromes P-450 can be very useful in exploring important clinical questions of hepatic drug metabolism. Expand
Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes.
TLDR
The SSAR of the various P450 enzymes ranges from the highly selective enzymes dealing with endogenous substrates, through the enzymes metabolising exogenous substrates with narrow substrate structure requirements such as P4502D to P4503A with its broad substrate structure range. Expand
Pharmacokinetic-Pharmacodynamic Consequences and Clinical Relevance of Cytochrome P450 3A4 Inhibition
TLDR
The clinical importance of any drug interaction depends on factors that are drug-, patient- and administration-related and is likely to be dependent on interindividual differences in CYP3A4 tissue content, pre-existing medical conditions and, possibly, age. Expand
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
TLDR
T careful evaluation of potential drug interactions of a new drug candidate during the early stage of drug development is essential, because the smaller the difference between toxic and effective concentration, the greater the likelihood that a drug interaction will have serious clinical consequences. Expand
An assay of flavin-containing monooxygenase activity with benzydamine N-oxidation.
TLDR
An assay system of flavin-containing monooxygenase was developed by fluorometric determination of benzydamine (BZY) N-oxidation with HPLC and rabbit antibody raised against the rat enzyme inhibited BZY N-Oxidation. Expand
Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9.
TLDR
Ketoconazole and sulphaphenazole can be used to establish the involvement of P4503A and 2C9 respectively in oxidative reactions in human liver microsomes and demonstrate an inhibitory effect on cyclosporine oxidase and testosterone 6 beta-hydroxylase activities. Expand
Antidepressant Drug Interactions and the Cytochrome P450 System
TLDR
The extent of the in vivo interaction between the SSRIs and tricyclic antidepressants mirrors to a large extent their in vitro inhibitory potencies against CYP2D6 and other isoenzyme systems, especially if one takes into account pharmacokinetic factors. Expand
Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450.
TLDR
Evaluating directly the P450 form selectivity of TAO, ANF, and DDC establishes that TAO is a selective inhibitor of the human CYP3A subfamily and that DDC cannot be employed as a diagnostic inhibitory probe for CYP2E1. Expand
...
1
2
3
...